Seven people involved in commercial bribery in Ganli pharmaceutical industry were arrested as domestic insulin giants

When some Chinese and foreign pharmaceutical companies are expecting the "GlaxoSmithKline business bribery incident" to be calming down, the legal network has just opened On the evening of January 8, a person from the Economic Investigation Department of Hubei Province told 21st century economic news: "in November 2013, the police have officially arrested seven medical representatives of Ganli pharmaceutical in Hubei, including provincial sales managers, regional managers and hospital representatives." In September 2013, anonymous sources revealed that Ganli pharmaceutical was involved in the commercial bribery scandal, and the total amount of bribery in 2012 may be as high as 300 million yuan Before the disclosure, the person had reported the case to the Economic Investigation Department of Hubei Province The economic investigation department began to investigate in August 2013 Ganli Pharmaceutical Co., Ltd is the only one that can produce the third generation insulin in China Its main competitors are Novo Nordisk, Lilly and Sanofi "29 people from Gansu and Li pharmaceutical's Hubei Office were taken away by the police for investigation, and 7 people were finally arrested When to enter the public prosecution and other procedures depends on the progress of handling the case, which is not known for the time being " The economic investigation department said According to it, due to the huge amount involved, the case has been listed as one of the major economic cases in Hubei Province for processing The provincial public security department and the health and Family Planning Commission have asked all the doctors in Hubei Province who have been bribed to return the stolen money At present, the total amount of the stolen money received is up to millions of yuan On January 9, 21st century economic news reporter contacted Ganli Pharmaceutical Co., Ltd to verify the matter The relevant person in charge said: "I haven't heard about it." According to the report materials of returning stolen goods of relevant doctors in the whole province, this growth is based on the huge amount of commercial bribery, and the relevant directors of Ganli pharmaceutical industry refuse to provide the contact information of Ganli's Hubei Office On the evening of January 8, the 21st century economic reporter found a medical representative in Wuhan who was responsible for promoting insulin products to understand the situation of doctors returning stolen goods "I only heard that urologists in several hospitals in Wuhan have had an affair with a domestic enterprise recently and are refunding money, but I don't see the official documents or know which company is involved." The medical representative said that the doctors who disclosed the information to him were also secretive and would not say more According to the information obtained by the 21st century economic reporter, not only Wuhan, but also Jingzhou, Shiyan and other cities in Hubei Province have doctors involved in the commercial bribery cases of Ganli pharmaceutical industry required to return the bribes According to the investigators, it is clear that the refund of the stolen money was made Earlier, the 21st century economic news reporter obtained internal information of Ganli pharmaceutical industry, which showed that there were hundreds of hospitals in Hubei Province doctors involved in bribery "The scope of this recovery of stolen money is mainly the 340 hospitals that take more bribes, and the ones that take less bribes are not involved for the time being," said the economic investigator "All the account books of Gansu and Li pharmaceutical Hubei Office have also been seized by the police," said the investigator But I don't know how their business is doing " The head of Ganli pharmaceutical headquarters also declined to provide any information about the Hubei Office of Ganli The 21st century economic report reporter learned from the above medical representatives that the Hubei Office of Ganli pharmaceutical industry is still in operation, but most hospitals have stopped selling their insulin products, and only some existing patients will receive some goods when they need them Before July 2013, Gan Li recruited a large number of medical representatives in Wuhan, Jingzhou, Enshi and other places in Hubei Province, but after July last year, similar online recruitment information did not appear again Ganli Pharmaceutical Co., Ltd is the only one that can produce the third generation insulin in China Its main competitors are Novo Nordisk, Lilly and Sanofi In the market competition with these giants, Ganli pharmaceutical industry can stand firm, but its market share increases year by year It wasn't until September 2013 that an anonymous tip off letter revealed the secrets of its growth In 2012, the number of new drug patients in Ganli pharmaceutical industry was 500000, surpassing foreign enterprises in some regional markets, but according to the report materials, this growth was based on a huge amount of commercial bribery The way of bribery includes the "project fee" of each new drug patient, the "AP fee" of each insulin rebate, and the "market fee" of maintaining doctor relationship at ordinary times In Hubei Province alone, there were more than 11000 new drug patients in Ganli pharmaceutical industry in 2012 According to the information provided by the informant at that time, for each new patient, the doctor can get about 200 yuan of "project cost" With this cost alone, the amount of bribes received by doctors in hospitals across the province is more than 2 million The AP fee of 20 yuan and the market fee of 5-7 yuan for each insulin are also included in the bribe fee of Ganli pharmaceutical industry Previous sources estimated that in 2012, the total amount of bribes paid by Gan Li in China could reach 300 million yuan According to the above investigators, the return of stolen goods is still in progress, so it is not sure how much money will eventually be collected The continuous anti-corruption of medicine should be "strictly investigated for three years": 2013 is the first year, 2014 and 2015 will also be strictly investigated, and will never relax the GlaxoSmithKline bribery case since its exposure, so far no case investigation progress has been published Therefore, some pharmaceutical companies believe that the impact of this event in 2014 will gradually fade Take the bribery case of Ganli pharmaceutical In September last year, when the informant provided clues to the 21st century economic report, he also provided clues to the Economic Investigation Department of Chaoyang District, Beijing, the Beijing Administration for Industry and commerce, the tax bureau and the Beijing Securities Regulatory Bureau, the headquarters of Ganli pharmaceutical Apart from the reply of "not under jurisdiction" from Beijing Securities Regulatory Bureau, there is no official response from the Department at present However, the Hubei Office of Ganli pharmaceutical industry suddenly heard the news of being investigated, and moved the topic of punishing medical commercial bribery to the front of the stage Industry insiders judge: "Hubei has such a big move, may have been recognized by higher authorities." Although in previous years, the health system will take "governance of commercial bribery in the field of medicine purchase and sale" as the focus of work in that year, from a series of actions started in the second half of 2013, this time the government level has clearly made a determination Around November 2013, many ministries and commissions, such as the health and Family Planning Commission and the Ministry of supervision, put forward that in the future, we will continue to rectify the industry style in the field of medicine, and we should "strictly investigate for three years" the anti-commercial bribery in the field of Medicine: 2013 is only the first year, 2014 and 2015 will also be strictly investigated, and we will never relax On December 26, 2013, the national health and Family Planning Commission and the State Administration of traditional Chinese medicine formulated "nine prohibitions" for strengthening the construction of medical and health practice, which clearly stipulated that "no kickbacks are allowed" In this context, the case of Ganli pharmaceutical industry seems to be more typical Previously, the materials provided by the informant to the 21st century economic reporter included the commercial bribery information of Ganli pharmaceutical in Hubei, Hunan, Jiangxi, Guizhou and other provinces At present, whether other provinces except Hubei start to investigate or not, the 21st century economic reporter has not got the official information The 21st century economic report will pay more attention to the development of Ganli pharmaceutical's suspected commercial bribery cases.